SCHEMBL4135426

SCHEMBL4135426

CN(Cc1cc(S(=O)(=O)c2cccnc2)n(-c2cccc(F)c2Cl)n1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.36
ABCC9 O60706 1/20 0.34
ABCC8 Q09428 1/20 0.34
KCNJ11 Q14654 1/20 0.34
KCNJ8 Q15842 1/20 0.34
PTGER2 P43116 6/20 0.33
HTT P42858 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
ALPL P05186 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130995 0.91 NAMPT (0.36) NAMPTABCC9ABCC8KCNJ11KCNJ8
SCHEMBL4125804 0.91 NAMPT (0.36) NAMPTABCC9ABCC8KCNJ11KCNJ8
SCHEMBL4131198 0.91 NAMPT (0.39) NAMPTABCC9ABCC8KCNJ11KCNJ8
SCHEMBL4123658 0.90 TAS2R14 (0.35) NAMPTPTGER2HTTKEAP1NFE2L2
SCHEMBL3699795 0.89 P2RX7 (0.34) NAMPTHTTGPBAR1
SCHEMBL4131139 0.88 ALDH1A1 (0.39) NAMPTHTTNFE2L2L3MBTL1
SCHEMBL4126098 0.87 NAMPT (0.39) NAMPTHTTKEAP1NFE2L2GPBAR1
SCHEMBL4131429 0.86 KEAP1 (0.36) NAMPTPTGER2KEAP1NFE2L2TAS2R14
SCHEMBL4126972 0.86 NAMPT (0.36) NAMPTABCC9ABCC8KCNJ11KCNJ8
SCHEMBL4126102 0.85 NAMPT (0.37) NAMPTABCC9ABCC8KCNJ11KCNJ8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 NAMPT 2129/4885ABCC9 455/4885ABCC8 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.